Can YKL-40 be a new inflammatory biomarker in cardiovascular disease?

Area of Science:

• Cardiology
• Biomarker Research
• Inflammation

Background:

• Coronary artery disease (CAD) remains a leading cause of mortality globally.
• Current treatments improve survival but many patients experience persistent symptoms and poor prognosis.
• There is a critical need for novel biomarkers to guide treatment and predict cardiovascular events in ischemic heart disease.

Purpose of the Study:

• To review existing literature on the inflammatory biomarker YKL-40 in cardiac patients.
• To evaluate the potential of YKL-40 as a biomarker for disease severity, prognosis, and survival in ischemic heart disease.
• To discuss the utility of YKL-40 in monitoring therapeutic interventions and prognostic evaluations.

Main Methods:

• Literature review of published studies on YKL-40 in cardiovascular disease.
• Analysis of YKL-40 levels in patients with acute and chronic ischemic heart disease.
• Discussion of YKL-40's correlation with clinical outcomes and treatment response.

Main Results:

• YKL-40 has been observed to be elevated in patients with both acute and stable chronic cardiovascular diseases.
• Preliminary findings suggest YKL-40 may be associated with disease severity and prognosis.
• Further research is warranted to confirm its role in monitoring treatment efficacy.

Conclusions:

• YKL-40 is a promising inflammatory biomarker in ischemic heart disease.
• It may serve as a valuable tool for assessing prognosis and guiding patient management.
• Its role in monitoring treatment requires further investigation and validation.